Diabetes impact on serum irisin level alongside other biochemical parameters

Media H. Ahmed; Saba  ZM. Al-Abachi

doi:10.5937/mckg57-45286

Media H. Ahmed Department of Chemistry, College of Science, University of Mosul, Mosul, Iraq
Saba ZM. Al-Abachi Department of Chemistry, College of Science, University of Mosul, Mosul, Iraq

DOI: https://doi.org/10.5937/mckg57-45286

Keywords: Irisin, FNDC5, Diabetes, Lipid profile, C-peptide

Abstract

Objective: The goal of the current study was to measure the irisin hormone level as well as certain other biochemical parameters associated with type 2 diabetes (T2D). Methods: A total of 65 type 2 diabetic patients were enrolled in this in this cross-sectional study versus 60 healthy subjects as a control group. The demographic data were recorded, and blood samples were withdrawn from patients and the control group. Serum separated and frozen for subsequent biochemical assays conducted for measured parameters, namely irisin, fasting serum glucose (FBS), insulin, C-peptide, total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), very low-density lipoprotein (VLDL-C) in the patients and control group. A fraction of blood samples were immediately processed for measurement of glycated haemoglobin (HbA1c). Results: There was a significant (p≤0.01) decrease in the irisin concentration in patients with T2D in comparison to the control group. Depending on sex, age and body mass index (BMI), the results have shown a non-significant difference in the irisin level, in patients with T2D or the control group. Conclusion: Irisin could be an additional measured parameter alongside lipid profile and glucose level in diabetic patients reflecting the patient status in term of prognosis or clinical follow-up.

References

1. Chachan TA, Farhan H, Hamed S. Determination of Irisin, Body Mass Index, and Other Biochemical Parameters in a Sample of Iraqi Type II Diabetic Patients. Journal of Techniques. 2022 Sep 30;4(3):53-9.

2. Campbell JE, Newgard CB. Mechanisms controlling pancreatic islet cell function in insulin secretion. Nature reviews Molecular cell biology. 2021 Feb;22(2):142-58.

3. Sanches JM, Zhao LN, Salehi A, Wollheim CB, Kaldis P. Pathophysiology of type 2 diabetes and the impact of altered metabolic interorgan crosstalk. The FEBS Journal. 2023 Feb;290(3):620-48.

4. Bereda G. Risk Factors, Complications and Management of Diabetes Mellitus. Am J Biomed Sci & Res. 2022; 16 (4): 409-412. AJBSR. MS. ID. 2022 Jun 9;2245.

5. Waseem R, Shamsi A, Mohammad T, Hassan MI, Kazim SN, Chaudhary AA, Rudayni HA, Al-Zharani M, Ahmad F, Islam A. FNDC5/irisin: physiology and pathophysiology. Molecules. 2022 Feb 8;27(3):1118.

6. Waseem R, Shamsi A, Mohammad T, Alhumaydhi FA, Kazim SN, Hassan MI, Ahmad F, Islam A. Multispectroscopic and molecular docking insight into elucidating the interaction of irisin with Rivastigmine tartrate: A combinational therapy approach to fight Alzheimer’s disease. ACS omega. 2021 Mar 8;6(11):7910-21.

7. Waseem R, Anwar S, Khan S, Shamsi A, Hassan MI, Anjum F, Shafie A, Islam A, Yadav DK. MAP/Microtubule affinity regulating kinase 4 inhibitory potential of irisin: A new therapeutic strategy to combat cancer and Alzheimer’s disease. International journal of molecular sciences. 2021 Oct 12;22(20):10986.

8. Kovalova Y, Sukhonos N, Brek V, Smolianyk K. Irisin, interleukin-33 and interleukin-37 in patients with ischemic heart disease and obesity. Medicinski časopis. 2021;55(3):87-93.

9. Marrano N, Biondi G, Borrelli A, Cignarelli A, Perrini S, Laviola L, Giorgino F, Natalicchio A. Irisin and incretin hormones: Similarities, differences, and implications in type 2 diabetes and obesity. Biomolecules. 2021 Feb 15;11(2):286.

10. Pesce M, Ballerini P, Paolucci T, Puca I, Farzaei MH, Patruno A. Irisin and autophagy: first update. International journal of molecular sciences. 2020 Oct 14;21(20):7587.

11. Korta P, Pocheć E, Mazur-Biały A. Irisin as a multifunctional protein: implications for health and certain diseases. Medicina. 2019 Aug 15;55(8):485.

12. Zhang D, Tan X, Tang N, Huang F, Chen Z, Shi G. Review of Research on the Role of Irisin in Tumors. OncoTargets and therapy. 2020;13:4423.

13. Pinkowska A, Podhorska-Okołów M, Dzięgiel P, Nowińska K. The role of irisin in cancer disease. Cells. 2021 Jun 12;10(6):1479.

14. Liu DM, Gan L, Su Y, Li F. Association between serum uric acid level and body mass index in sex-and age-specific groups in southwestern China. Endocrine Practice. 2019 May 1;25(5):438-45.

15. Gan W, Chen W, Li T, Shao D, Xu F, Huo S, Li C, Yang Z, Zeng X. Circulating irisin level in chronic kidney disease patients: A systematic review and meta-analysis. International Urology and Nephrology. 2022 Jun 1:1-8.

16. Dominiczak MH. Tietz textbook of clinical chemistry. By CA Burtis and ER Ashwood, editors.

17. Manley SE, Stratton IM, Clark PM, Luzio SD. Comparison of 11 human insulin assays: implications for clinical investigation and research. Clinical chemistry. 2007 May 1;53(5):922-32.

18. Johansen OE, Boehm BO, Grill V, Torjesen PA, Bhattacharya S, Patel S, Wetzel K, Woerle HJ. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes care. 2014 Jan 1;37(1):e11-2.

19. Faria MS, de Aguilar-Nascimento JE, Pimenta OS, Alvarenga LC, Dock-Nascimento DB, Slhessarenko N. Preoperative fasting of 2 hours minimizes insulin resistance and organic response to trauma after video-cholecystectomy: a randomized, controlled, clinical trial. World journal of surgery. 2009 Jun;33:1158-64.

20. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clinical chemistry. 1982 Oct 1;28(10):2077-80.

21. Young DS. Effects of drugs on clinical laboratory tests. Annals of clinical biochemistry. 1997 Nov;34(6):579-81.

22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry. 1972 Jun 1;18(6):499-502.

23. Osei-Yeboah J, Owiredu WK, Norgbe GK, Yao Lokpo S, Gyamfi J, Alote Allotey E, Asumbasiya Aduko R, Noagbe M, Attah FA. The prevalence of metabolic syndrome and its components among people with type 2 diabetes in the Ho Municipality, Ghana: a cross-sectional study. International journal of chronic diseases. 2017 Feb 12;2017.

24. Song Z, XU G, MA H, Wang Q. Determination of glycated hemoglobin standardization situation. Chinese Journal of Laboratory Medicine. 2012:497-500.

25. Elizondo-Montemayor L, Gonzalez-Gil AM, Tamez-Rivera O, Toledo-Salinas C, Peschard-Franco M, Rodríguez-Gutiérrez NA, Silva-Platas C, Garcia-Rivas G. Association between irisin, hs-CRP, and metabolic status in children and adolescents with type 2 diabetes mellitus. Mediators of inflammation. 2019 Mar 20;2019.

26. Pignataro P, Dicarlo M, Zerlotin R, Zecca C, Dell’Abate MT, Buccoliero C, Logroscino G, Colucci S, Grano M. FNDC5/Irisin system in neuroinflammation and neurodegenerative diseases: update and novel perspective. International Journal of Molecular Sciences. 2021 Feb 5;22(4):1605.

27. Xuan X, Lin J, Zhang Y, Zhou L, Xu L, Jia J, Zhao B, Lin Z, Zhu Q, Li L, Wu T. Serum irisin levels and clinical implication in elderly patients with type 2 diabetes mellitus. Journal of Clinical Medicine Research. 2020 Sep;12(9):612.

28. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C. Pathophysiology of type 2 diabetes mellitus. International journal of molecular sciences. 2020 Jan;21(17):6275.

29. Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: Review of the underlying molecular mechanisms. Journal of cellular physiology. 2019 Jun;234(6):8152-61.

30. Fultang J, Chinaka U, Rankin J, Bakhshi A, Ali A. Preoperative bariatric surgery predictors of type 2 diabetes remission. Journal of Obesity & Metabolic Syndrome. 2021 Jun 6;30(2):104.

31. Washburn RL, Mueller K, Kaur G, Moreno T, Moustaid-Moussa N, Ramalingam L, Dufour JM. C-peptide as a therapy for type 1 diabetes mellitus. Biomedicines. 2021 Mar 8;9(3):270.

32. Ibrahim I, Salih S. Serum Irisin In Individuals with Type 2 Diabetes Mellitus and Prediabetes in Duhok City. Journal of Life and Bio Sciences Research. 2022 Oct 26;3(02):59-64.

33. Sunil B, Ashraf AP. Dyslipidemia in pediatric type 2 diabetes mellitus. Current diabetes reports. 2020 Oct;20:1-9.

34. Arpón A, Santos JL, Milagro FI, Cataldo LR, Bravo C, Riezu-Boj JI, Martínez JA. Insulin sensitivity is associated with lipoprotein lipase (LPL) and Catenin Delta 2 (CTNND2) DNA methylation in peripheral white blood cells in non-diabetic young women. International journal of molecular sciences. 2019 Jun 15;20(12):2928.

35. Merkhan MM, Shephard MT, Forsyth NR. Physoxia alters human mesenchymal stem cell secretome. Journal of Tissue Engineering. 2021 Oct;12:20417314211056132.

36. Shephard MT, Merkhan MM, Forsyth NR. Human Mesenchymal Stem Cell Secretome Driven T Cell Immunomodulation Is IL-10 Dependent. International Journal of Molecular Sciences. 2022 Nov 6;23(21):13596.